Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 5
Submit an article Journal homepage
139
Views
3
CrossRef citations to date
0
Altmetric
Original Articles: Research

Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia

Vasiliki PapadopoulouHematology Unit, 1st Department of Internal Medicine, Laiko Hospital, University of Athens, Athens, Greece; Correspondence[email protected]
,
Elina KontandreopoulouHematology Unit, 1st Department of Internal Medicine, Laiko Hospital, University of Athens, Athens, Greece;
,
Panayiotis PanayiotidisMolecular Hematology Laboratory, 1st Department of Propaedeutic Medicine, University of Athens, Athens, Greece;
,
Maria RoumeliotiMolecular Hematology Laboratory, 1st Department of Propaedeutic Medicine, University of Athens, Athens, Greece;
,
Maria AngelopoulouHematology Department, Laiko Hospital, University of Athens, Athens, Greece;
,
Lydia KyriazopoulouHematology Department, University of Ioannina Medical School, Ioannina, Greece;
,
Panagiotis T. DiamantopoulosHematology Unit, 1st Department of Internal Medicine, Laiko Hospital, University of Athens, Athens, Greece;
,
George VaiopoulosHematology Unit, 1st Department of Internal Medicine, Laiko Hospital, University of Athens, Athens, Greece;
,
Eleni VariamiHematology Unit, 1st Department of Internal Medicine, Laiko Hospital, University of Athens, Athens, Greece;
,
Ioannis KotsianidisHematology Department, Democritus University of Thrace Medical School, Xanthi, Greece
&
Nora Athina ViniouHematology Unit, 1st Department of Internal Medicine, Laiko Hospital, University of Athens, Athens, Greece;
show all
Pages 1182-1188 | Received 18 Jul 2015, Accepted 30 Aug 2015, Published online: 23 Dec 2015

References

  • O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.
  • Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325.
  • Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 2009; 2009: 461–476.
  • Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011; 25: 7–22.
  • Lee H, Yi JS, Lawan A, et al. Mining the function of protein tyrosine phosphatases in health and disease. Semin Cell Dev Biol 2015; 37: 66–72.
  • Liedtke M, Pandey P, Kumar S, et al. Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. Oncogene 1998; 17: 1889–1892.
  • Lim YM, Wong S, Lau G, et al. BCR/ABL inhibition by an escort/phosphatase fusion protein. Proc Natl Acad Sci U S A 2000; 97: 12233–12238.
  • LaMontagne KR Jr, Hannon G, Tonks NK. Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells. Proc Natl Acad Sci U S A 1998; 95: 14094–14099.
  • Shultz LD, Schweitzer PA, Rajan TV, et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 1993; 73: 1445–1454.
  • Alsadeq A, Hobeika E, Medgyesi D, et al. The role of the Syk/Shp-1 kinase-phosphatase equilibrium in B cell development and signaling. J Immunol 2014; 193: 268–276.
  • Tsantikos E, Maxwell MJ, Kountouri N, et al. Genetic interdependence of Lyn and negative regulators of B cell receptor signaling in autoimmune disease development. J Immunol 2012; 189: 1726–1736.
  • Tauchi T, Ohyashiki K, Yamashita Y, et al. SH2-containing phosphotyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways. Int J Oncol 1997; 11: 471–475.
  • Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005; 8: 355–368.
  • Chen W, Wang Z, Jiang C, et al. PP2A-Mediated Anticancer Therapy. Gastroenterol Res Pract 2013; 2013: 675429.
  • Oka T, Yoshino T, Hayashi K, et al. Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Am J Pathol 2001; 159: 1495–1505.
  • Chim CS, Fung TK, Cheung WC, et al. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 2004; 103: 4630–4635.
  • Amin HM, Hoshino K, Yang H, et al. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J Pathol 2007; 212: 402–410.
  • Kaeda J, Neuman D, Bonecker S, et al. Differential expression of SHP-1 in chronic myeloid leukemia. Leuk Lymphoma 2015; 56: 1547–1549.
  • Oka T, Ouchida M, Koyama M, et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 2002; 62: 6390–6394.
  • Esposito N, Colavita I, Quintarelli C, et al. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood 2011; 118: 3634–3644.
  • Evren S, Wan S, Ma XZ, et al. Characterization of SHP-1 protein tyrosine phosphatase transcripts, protein isoforms and phosphatase activity in epithelial cancer cells. Genomics 2013; 102: 491–499.
  • Nakase K, Cheng J, Zhu Q, et al. Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1-transformed T cells. J Leukoc Biol 2009; 85: 165–174.
  • Bose S, Deininger M, Gora-Tybor J, et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362–3367.
  • Li Y, Yang L, Pan Y, et al. Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia. Oncol Rep 2014; 31: 2438–2446.
  • Xu D, Qu CK. Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci 2008; 13: 4925–4932.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.